SNDL
SNDL, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.24
−4.62%Oct 27, 2026, 12:26 UTC
SNDL Inc. reported a quarterly loss of $0.03 per share, compared with a loss of $0.04 per share a year earlier.
Oct 15, 2026, 21:00 UTC
SNDL Inc. said it intends to accelerate its return of capital.
Source:Oct 15, 2026, 21:00 UTC
SNDL Inc. announced its 2026 annual and special shareholders meeting results.
Source:Oct 15, 2026, 21:00 UTC
SNDL Inc. reported preliminary third-quarter free cash flow of approximately C$20 million, a record quarterly level.
Source:Oct 14, 2026, 20:30 UTC
SNDL announced that it will release its third-quarter 2026 financial results before markets open on October 27, 2026.
Source:Oct 6, 2026, 11:00 UTC
Carlo Cannell resigned from the Board of Directors of SNDL Inc. effective immediately.
Source:Aug 4, 2026, 20:30 UTC
SNDL Inc. announced the successful completion of an EU-GMP audit at its Atholville, New Brunswick cultivation facility on August 4, 2026.
Source:Jul 28, 2026, 10:55 UTC
SNDL accelerated its share repurchase program.
Jul 28, 2026, 10:55 UTC
SNDL reported its financial and operational results for the second quarter of 2026.
Jul 27, 2026, 15:48 UTC
SNDL Inc. completed the acquisition of certain assets of Surterra Holdings, Inc. (Parallel), a U.S. vertically integrated cannabis operator with operations in Florida, Texas and Massachusetts.